Trial Condition(s):
Atrial Fibrillation
Analysis of the Potential savings of Rivaroxaban Events versus Vitamin K Antagonists events
Bayer Identifier:
18231
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.
Inclusion Criteria
- Older than 18 years - Diagnosis of non-valvular AF (ICD code 427.31) - Pharmacological treatment with VKAs or rivaroxaban following diagnosis
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Granada, Spain | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Estimate of costs associated with atrial fibrillation treatment with Rivaroxaban versus Vitamin K Antagonists
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Time in therapeutic range (TTR) values in the last 6 monthsTimeframe: 6 months
- Presence of strokePresence of stroke prior and subsequent to treatmentTimeframe: 12 months
- Active substance receivedRivaroxaban or VKAs (Acenocoumarol and Warfarin)Timeframe: 12 months
Secondary Outcome
- Date of strokeTimeframe: 12 months
- Type of strokeType of stroke acccording to patients group: unknown, haemorrhagic or ischaemic.Timeframe: 12 months
- Duration of treatment (in days)Timeframe: 12 months
- Dose of the prescribed treatmentTimeframe: 12 months
- Frequency of the prescribed treatment (in hours)Timeframe: 12 months
Additional Information
Copyright © Bayer
Powered by
